TELA Bio Inc. Chief Executive Officer Heather C. Getz acquired 12,500 common shares on Aug. 17, according to an SEC filing disclosed Aug. 26. The purchase totaled $8,311 at weighted average prices between $0.6504 and $0.6749 per share, bringing her direct holdings to 532,500 shares.
The transaction follows TELA Bio’s second-quarter results, which showed a net loss of $0.20 per share on revenue of $19.3 million, both below Wall Street estimates. Analysts had forecast a loss of $0.17 per share on revenue of $21.04 million. The company also withdrew its full-year 2026 revenue guidance, citing slower-than-expected sales force expansion and weaker first-half performance.
OviTex unit volume rose 12% year-over-year, but revenue in the plastic and reconstructive surgery segment declined 24.7%, weighing on total sales. Gross margin improved to 72% from 70% in the prior-year period, supported by tariff refunds and reduced inventory charges. TELA Bio’s shares were trading at $0.70 on Aug. 26, up roughly 8% from the prior week, valuing the company at $31.43 million.
